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Summary  Pneumococcal  disease  has  substantial  incidence,  morbidity  and  mor-
tality  in  older  adults.  Decreased  birth  rates  and  longer  lifespans  indicate  that  the
global  population  is  aging,  although  rates  of  aging  differ  between  countries  [1].  InCommunity-acquired 2010,  the  proportion  of  the  population  aged  >60  years  in  the  general  Arab  Regionpneumonia (CAP);
Pneumococcal vaccines;
Vaccination;
was  7%,  and  this  proportion  is  expected  to  rise  to  19%  by  2050  for  the  region  as  a
whole  [2];  the  United  Nations  estimates  for  the  individual  countries  of  the  Arabian
Gulf  by  2050  are  25.7%,  24.9%,  20.7%,  26.7%  and  10.5%  in  the  Kuwait,  Bahrain,  Qatar,
United  Arab  Emirates  (UAE)  and  Oman,  respectively,  which  are  comparable  to  the
26.9%  predicted  for  the  USA  and  lower  than  that  predicted  in  European  countries,
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in  which  the  2050  estimates  are  32.7%,  34.0%  and  38.1%  for  France,  the  UK  and
Germany,  respectively  [1].  Globally  and  in  the  Gulf  Region,  pneumococcal  disease
is  an  increasingly  important  public  health  burden  in  the  elderly.
The  burden  of  pneumococcal  disease  can  be  reduced  by  effective  vaccination  pro-
grams,  but  the  recommendations  on  pneumococcal  vaccination  in  adults  vary  widely.
The  major  barriers  to  vaccine  implementation  among  healthcare  professionals  are  an
incomplete  awareness  of  pneumococcal  disease  and  the  vaccination  options  in  adults.
The  Gulf  Advocate  Group  calls  for  healthcare  providers  in  the  countries  of  the  Arabian
Gulf  (Kuwait,  Bahrain,  Qatar,  United  Arab  Emirates  and  Oman)  to  support  awareness
and  education  programs  about  adult  pneumococcal  disease,  particularly  in  high-risk
groups  such  as  those  >65  years  of  age,  those  with  type  2  diabetes  mellitus,  hema-
tological  malignancy,  organ  and  bone  marrow  transplantation  or  chronic  kidney  or
lung  diseases  and  pilgrims  undertaking  the  Hajj  to  improve  pneumococcal  disease
surveillance  and  optimize  and  disseminate  recommendations  for  adult  vaccination.
The  Gulf  Advocate  Group  recommends  following  the  U.S.  Centers  for  Disease  Control
and  Prevention  (CDC)  guidelines  for  pneumococcal  vaccination  [3,4].
Elderly adults;
Type 2 diabetes;
Hajj pilgrims
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Respiratory infections represent a
signiﬁcant burden globally
Respiratory  infections  are  a  signiﬁcant  cause  of
mortality  worldwide  [5,6].  Twenty-ﬁve  percent  of
deaths globally  are  due  to  infectious  diseases,
with respiratory  infections  ranked  as  the  lead-
ing infectious  disease  cause  of  mortality  [7];
considering  global  deaths  from  all  causes,  lower
respiratory  tract  infections  (LRTIs)  are  ranked  third
[7,8].  Global  mortality  due  to  respiratory  infections
exceeds the  total  mortality  from  HIV  infection,
malaria and  diarrheal  diseases  combined.  Although
the speciﬁc  incidences  and  mortalities  may  vary
from  region  to  region  and  between  studies,  the
of  the  cases  of  CAP),  among  these  cases,  pneu-
mococcus is  by  far  the  most  frequently  identiﬁed
pathogen. For  the  elderly  in  developed  countries,
pneumococcus is estimated  to  cause  25—50%  of
CAP cases  requiring  hospitalization  [9].  Pneumococ-
cal disease  is  a considerable  health  problem,  and
even in  countries  with  a sophisticated  healthcare
system, pneumococcal  disease  is  associated  with
an elevated  hospitalization  rate  that  consequently
represents a large  economic  burden  to  society.
Pneumococcal disease: a major
preventable health burdenburden  of  community-acquired  pneumonia  (CAP)  is
substantial in  all  parts  of  the  world.  While  the  etiol-
ogy is  often  difﬁcult  to  establish  (determination  of
a microbial  cause  occurs  in  approximately  one-half
S
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ttreptococcus  pneumoniae  causes  invasive  and  non-
nvasive pneumococcal  diseases.  These  invasive
iseases  include  bacteremic  pneumonia,  bac-
eremia  without  a  focus  and  meningitis.  The
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ajority  of  the  cases  of  invasive  pneumococcal
isease (IPD)  in  adults  present  as  bacteremic  pneu-
onia,  and  IPD  is  associated  with  case-fatality  rates
f 15—25%  among  elderly  adults  [10—13].
While etiological  veriﬁcation  of  CAP  and  the
etection of  bacteremia  in  clinical  practice  may
e challenging,  a  signiﬁcant  proportion  of  CAP  is
ttributable  to  S.  pneumoniae. In  multiple  Euro-
ean  studies  investigating  the  etiology  of  CAP,  S.
neumoniae  was  the  most  frequently  identiﬁed
athogen, regardless  of  age  group,  clinical  severity
r country  [14,15]. In  the  USA,  it  is  estimated  that
he annual  burden  of  pneumococcal  disease  is  as
igh as  30,000  cases  of  IPD,  500,000  cases  of  CAP,
nd 25,000  deaths  in  adults  over  65  years  of  age
16].  The  rates  of  CAP  hospitalization  and  CAP  mor-
ality remain  especially  high  in  older  adults,  despite
pparent  advances  in  therapy  and  preventive  meas-
res.
ging and other risk factors for
neumococcal diseases
he  incidence  of  pneumococcal  disease  peaks  in
nfancy and  then  again  from  mid-life  onward  (>45
ears of  age),  with  a  particularly  steep  increase  at
pproximately  60  years  of  age,  although  there  may
e regional  differences  in  this  pattern;  for  exam-
le, in  the  Republic  of  South  Africa,  the  incidence
urve is W-shaped  rather  than  the  traditional  U-
haped curve,  with  an  additional  peak  observed  in
ounger adults  due  to  the  HIV  epidemic  [17,18].
onsidering  the  range  of  risk  factors  associated  with
neumococcal  disease,  age  has  been  shown  to  be
n independent  risk  factor  and  one  that  should  be
either neglected  nor  under-estimated.
Aging is a  widely  recognized  risk  factor  for
neumococcal disease,  due  in  part  to  the  natu-
al biological  process  of  immune  senescence  for
cquired  or  adaptive  immunity  [19,20].  The  quality
f the  immune  response  may  decline  with  advanc-
ng age,  resulting  in  increased  susceptibility  to
nfections  and  pathological  conditions  related  to
nﬂammation  or  autoimmune  diseases  [21].  The
odiﬁcation  of  immunity  with  age  leads  to  changes
n the  function  of  macrophages,  neutrophils,  den-
ritic cells  and  natural  killer  cells.  This  ﬁnding
s exempliﬁed  by  reduced  phagocytic  and  oxida-
ive burst  capacities,  impaired  up-regulation  of  the
ajor histocompatibility  complex  (MHC)  class  II  in
acrophages  and  defective  expression  of  toll-like
eceptors  (TLRs),  leading  to  inadequate  immune
esponses  [20]  and  increased  susceptibility  to  infec-
ious diseases.
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In  addition  to  aging,  host  factors  such  as
o-morbidities (for  example,  chronic  cardio-
espiratory disorders  or  diabetes  mellitus)  and
ther factors,  such  as  cigarette  smoking  and  resi-
ence  in  long-term  care  facilities  or  imprisonment,
ave been  established  as  major  risk  factors  for
neumococcal  disease  [22—26], and  these  factors
re reﬂected  in  the  World  Health  Organization
osition on  pneumococcal  vaccination  [27].  In
ountries  of  the  Arabian  Gulf,  the  prevalence  of
ype 2  diabetes  mellitus  is among  the  highest  in  the
orld [28,29],  ensuring  that  this  co-morbidity  is  a
ubstantial risk  factor  for  pneumococcal  disease  in
he region  (Table  1).
neumococcal disease in the Arabian
ulf
ith  respect  to  pneumococcal  disease  among
dults, few  studies  have  been  published  from  the
ulf States  or  neighboring  countries,  and  those  that
ave been  undertaken  have  been  limited;  however,
here are  published  data  available  that  can  inform
ecision  making.
A retrospective  analysis  in  the  UAE  examined  the
ates of  community-  and  hospital-acquired  pneu-
onia from  1997  to  2002.  The  criteria  for  the
iagnosis  of  CAP  were  symptoms  of  acute  onset
ough, fever  and  new  focal  inﬁltrates  on  the  chest
adiograph,  with  or  without  the  isolation  of  a
athogen  from  sputum  or  blood  culture.  The  aver-
ge age  of  the  patients  was  58  years,  and  the
ost common  co-morbidities  were  diabetes  melli-
us (21%),  malignancy  (20%)  and  chronic  obstructive
ulmonary  disease  (COPD)  (19%).  From  CAP  cases
ocumented  through  sputum  cultures,  9%  were
dentiﬁed  as  caused  by  S.  pneumoniae  [30]. A  ret-
ospective  review  of  data  from  567  adult  patients
ith pneumonia  in  the  Kingdom  of  Saudi  Arabia
as undertaken  to  investigate  the  major  pathogens
ausing CAP  based  on  nasopharyngeal  carriage.  The
ean age  of  the  patients  was  43  years  (SD  22
ears). The  clinical  histories  were  available  for  305
atients,  which  indicated  that  25%  had  type  2 dia-
etes mellitus  (76/305),  and  54%  in  total  had  one
r more  co-morbidities  [28].
Oman undertook  a  retrospective  analysis  of
ospital records  for  blood  culture-positive  S.  pneu-
oniae cases  and  determined  associated  riskactors.  The  study  population  (n  =  120)  included
hildren and  adults;  16.7%  were  aged  over  60
ears, and  co-morbidities  (deﬁned  as  splenectomy,
iabetes mellitus,  chronic  liver/renal  disease  or
404  C.  Feldman  et  al.
Table  1  Common  co-morbidities  observed  in  patients  hospitalized  with  CAP  in  Saudi  Arabia  and  the  United  Arab
Emirates  [28,30,62].
Saudi  Arabia,  n
(%)  [28]
United  Arab
Emirates,  n  (%)  [62]
United  Arab  Emirates,
n  (%)  [30]
N  305  236  361
Mean  age 42.7  years  58  years  59  years  (males)
56.9  years  (females)
Diabetes  mellitus 76  (24.9) 56  (23.7) 77  (21)
Asthma  61  (20.0)  —  —
COPD  39  (12.8)  46  (19.5)  68  (19)
Malignancy  40  (13.1)  —  72  (20)
Heart/cardiovascular  disease  35  (11.5)  16  (7)  —
Neurologic  disorders/stroke  31  (10.2)  21  (9)  —
Liver  disease/disorders  24  (7.9)  —  —
Renal  failure  17  (5.6)  16  (7)  —
HIV  —  2  (1)  5  (1.4)
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CAP, community-acquired pneumonia; COPD, chronic obstructi
malignancy)  were  recorded  in  69.2%  of  the  patients
[31].
In the  Arabian  Gulf,  signiﬁcant  risk  factors  for
pneumococcal  disease  appear  to  exist,  and  some
risk factors  are  similar  to  those  occurring  in  other
parts of  the  world,  while  others  are  distinctive  risk
factors for  the  region,  such  as  the  Hajj,  during
which over  2 million  pilgrims  from  160  countries
gather in  Mecca  [32]. During  this  period,  pneumo-
nia accounts  for  one-third  of  the  hospitalizations  in
Saudi Arabia  [33,34], with  S.  pneumoniae  being  the
leading cause  [35].
The value of pneumococcal surveillance
More  than  90  pneumococcal  serotypes  have  been
characterized,  but  clinical  disease  is  associated
with a relatively  few  serotypes  [27].  Overall
serotype distribution  may  be  affected  by  a number
of factors,  including  the  nature  of  the  epi-
demiological study  (age  groups  targeted,  clinical
presentations represented,  period  of  surveillance
and whether  the  surveillance  was  active  or  pas-
sive) and  the  antibiotic  prescribing  habits.  Serotype
coverage  of  a  pneumococcal  vaccine  based  on
knowledge of  the  serotypes  prevailing  in  any  partic-
ular region  is  of  value  in  estimating  the  anticipated
effectiveness of  immunization  strategies  in  that
region.
Diagnosis  of  IPD  requires  laboratory  analysis
that cannot  be  established  without  adequate  infra-
structure  and  resources.  Reliable  epidemiological
data for  a  country  or  region  depends  on  the  quality
of surveillance  systems  in  place,  which  requires
close collaboration  between  laboratory  and
t
o
a
i82  (35)  —
lmonary disease; HIV, human immunodeﬁciency virus.
linical  facilities.  Systems  such  as  those  used  by
he Health  Protection  Agency  (HPA)  in  the  UK  and
he Centers  for  Disease  Control  and  Prevention
CDC) in  the  USA  follow  the  incidence  of  a  number
f invasive  bacterial  infections,  including  pneumo-
occus.  Long-standing  surveillance  data  from  the
SA and  Europe  have  provided  profound  insight  into
he diverse  clinical  presentations  of  pneumococcal
isease, the  serotype  prevalence,  and  the  impact
f pneumococcal  vaccination  programs  to  date,
lthough  problems  of  under-reporting  continue  in
any countries.
Surveillance  of  IPD  is  not  compulsory  in  the
ulf States,  and  thus,  the  disease  burden  is  often
nder-reported.  While  the  notiﬁcation  service  for
nfectious  diseases  in  Dubai,  UAE,  receives  an
verage  of  11,000  infectious  disease  notiﬁcations
nnually, S.  pneumoniae  is  not  highly  represented
n this  sample,  and  there  is  no  speciﬁcation  of
erotype.  With  respect  to  clinical  presentation,
mong those  11,000  infectious  disease  notiﬁca-
ions, only  750  cases  of  pneumonia,  and  35  cases  of
acterial meningitis  were  observed  on  average  each
ear, suggesting  that  there  is  a need  to  enhance
ase notiﬁcation  [36].
neumococcal vaccinations in adults:
ecommendations versus
mplementation
he  public  health  value  of  pneumococcal  preven-
ion through  vaccination  with  subsequent  lowering
f disease  incidence  is  well  documented  in  pedi-
tric populations;  the  value  of  vaccination  in  adults
s often  under-appreciated.  The  preventative
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otential  of  adult  pneumococcal  vaccination  is  par-
icularly neglected  in  the  Gulf  States  because  there
s a  low  awareness  of  the  burden  of  pneumococcal
isease in  adults  and  an  under-recognition  of  the
otential  beneﬁt  of  preventative  measures.
The 23-valent  pneumococcal  polysaccharide
accine  (PPSV23)  has  been  recommended  for  all
dults aged  ≥65  years  in  the  USA,  with  overall
accination rates  being  approximately  60%  [37,38].
evertheless,  the  impact  on  the  incidence  of  dis-
ase has  not  been  substantiated  at  a  population
evel [39].
A recent  Cochrane  Group  publication  concluded
hat ‘‘the  meta-analysis  does  not  provide  com-
elling  evidence  to  support  the  routine  use  of
neumococcal  polysaccharide  vaccine  to  prevent
ll-cause  pneumonia  or  mortality’’  [40].  The  Joint
ommittee  on  Vaccination  and  Immunization  (JCVI)
f the  UK  recommended  the  discontinuation  of  rou-
ine use  of  the  PPV23  in  older  adults  in  March
011, although  this  committee  subsequently  issued
 statement  in  July  of  the  same  year  concluding
hat ‘‘whilst  uncertainty  remains  about  the  effec-
iveness  of  PPSV23,  there  is  better  evidence  from
he UK  experience  of  the  vaccine  suggesting  that
PSV23  provides  some  moderate  short-term  pro-
ection to  those  aged  65  years  and  older,  although
rotection may  be  less  and  wane  faster  in  older  age
roups and  for  some  clinical  risk  groups’’.  At  the
resent  time,  the  recommendation  for  its  use  still
emains in  place  [41].
The 13-valent  pneumococcal  conjugate  vaccine
PCV13) is  now  licensed  in  a  number  of  countries
or adults  >50  years  of  age  based  on  demon-
tration of  a  functional  immune  response  that
s non-inferior  or  superior  to  PPV23  for  the  12
erotypes that  are  common  to  the  two  vaccines
42—44].  When  serotype-speciﬁc  opsonophagocytic
ctivity (OPA)  was  measured  in  two  pivotal  clin-
cal trials,  PCV13  was  found  to  be  non-inferior
r superior  to  PPSV23  in  both  adults  who  had
ever received  the  PPV23  and  adults  who  had
eceived a  dose  of  PPV23  at  least  ﬁve  years  ear-
ier [45,46].  As  a  result,  the  conjugate  vaccine
ay be  used  in  vaccine  naïve  adults  and  in  those
reviously  immunized  with  PPV23  (for  whom  revac-
ination  with  a  polysaccharide  vaccine  is  generally
ot recommended).  Furthermore,  PCV13  vacci-
ation  can  induce  immune  responses  that  are
ssociated with  the  induction  of  immune  mem-
ry, whether  demonstrated  years  later  by  a PCV13
evaccination  or  with  a  challenge  dose  of  PPV23
45].  Induction  of  immunological  memory  may  be
entral to  a  successful  immune  response.  In  con-
rast with  the  polysaccharide-conjugate  vaccine,  a
olysaccharide  vaccine  provides  a  T-independent
p
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mmune  response  that  results  in  short-lived  B-
ell responses  without  production  of  memory  B
ells [47,48]. Consequently,  this  conjugate  vac-
ine (PCV13)  may  prime  the  immune  system,  which
otentially  could  enhance  and  prolong  a  protective
mmune response.
In the  USA,  where  PCV13  was  recently  licensed
y the  FDA  for  use  in  adults  aged  >50  years,
he Advisory  Committee  on  Immunization  Practices
ACIP)  recently  issued  recommendations  for  use  of
CV13 in  adults  aged  >19  years  with  immunocom-
romising conditions  (i.e.,  sickle  cell  disease/other
emoglobinopathies;  congenital  or  acquired  asple-
ia; congenital  or  acquired  immunodeﬁciency;  HIV
nfection;  chronic  renal  failure;  nephrotic  syn-
rome;  leukemia;  lymphoma;  Hodgkin’s  disease;
eneralized  malignancy;  iatrogenic  immunosup-
ression; solid  organ  transplant;  and  multiple
yeloma), functional  or  anatomic  asplenia,  cere-
rospinal  ﬂuid  (CSF)  leaks  or  cochlear  implants  [4].
Many countries  follow  the  CDC  guidelines  for
neumococcal vaccination;  however,  individual
ountry recommendations  have  often  been  estab-
ished,  such  as  in  the  Gulf  States  (Table  2).  In  the
nited Arab  Emirates  (UAE),  adults  with  type  2  dia-
etes are  offered  PPSV23  in  primary  healthcare.  In
man, the  recommendations  follow  the  former  CDC
uidelines  of  giving  up  to  two  doses  of  PPV23  over
 lifetime,  with  vaccination  as  standard  practice
or individuals  with  HIV  infection  [49]. In  Qatar,
here are  new  recommendations  for  the  use  of  a
ingle dose  of  PCV13  in  adults  >50  years  of  age,  with
hose previously  vaccinated  receiving  a single  dose
f PCV13  administered  ﬁve  years  after  the  last  dose
f PPV23;  additionally,  it  is  recommended  that  high-
isk adults  aged  19—64  years  are  administered  a
ingle dose  of  PCV13  at  an  interval  at  least  one  year
rom the  last  dose  of  PPV23  and  that  adults  who
ave not  been  previously  vaccinated  are  adminis-
ered  a single  dose  of  PCV13,  followed  by  PPV23
ight weeks  later  [50]. In  Kuwait,  vaccination  with
PV23 is  given  to  individuals  >2  years  of  age  who
re at  high  risk  of  pneumococcal  disease;  in  younger
atients,  PCV13  is  used  as  routine  vaccination.  All
dults with  underlying  disease  and  those  aged  >65
re vaccinated  with  PPV23,  which  may  or  may  not
e administered  at  the  same  time  as  the  annual
nﬂuenza vaccination  [51]. In  addition,  PPV23  vac-
ination is  recommended  for  all  adults  undertaking
he Hajj  pilgrimage,  regardless  of  age  or  underlying
isease [52].
However,  although  general  vaccination  for  Hajjilgrims  has  been  discussed  and  acknowledged  in
he literature  and  by  some  countries  [53,54], it is
ot speciﬁcally  recommended  by  the  Saudi  Ministry
f Health  [55,56]  or  WHO  [57]. In  fact,  very  few
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Table  2  Adult  pneumococcal  vaccine  recommendations  in  countries  of  the  Arabian  Gulf  (United  Arab  Emirates,
Qatar,  Kuwait,  Bahrain,  Oman).
Country  Pneumococcal  vaccine  recommendations  in  adults
Bahrain  [63,64]  Single  dose  of  PPV23  for  ≥65  years  and  single  dose  of  PPV23  for  high  risk
groups  ≥2—64  years,  with  a booster  after  ﬁve  years
Kuwait  [52] Healthcare  workers  and  elderly  at  risk  of  pneumococcal
disease,  including  those  with  asplenia,  immunosuppressive
disease,  cancer,  chronic  renal  and  hepatic  diseases,
chronic  pulmonary  diseases,  chronic  cardiovascular
diseases,  insulin-dependent  diabetes,  asthma,  blood
diseases,  and  all  pilgrims  undertaking  the  Hajj
Oman  [63]  PPV23,  up  to  2  doses  in  a  lifetime
Qatar  [50] Healthy  adults
over  50  years
If vaccinated
with  PPV23
A single  dose  of
PCV13  ﬁve  years
from  last  PPV23
If  unvaccinated
with  PPV23
A single  dose  of
PCV13
High-risk  adults
19—64  years
If vaccinated
with  PPV23
A single  dose  of
PCV13  one  year
from  last  PPV23
If  unvaccinated
with  PPV23
A single  dose  of
PCV13  then
PPV23  after  eight
weeks
United  Arab  Emirates
[63,65]
High-risk  groups
Hajj  pilgrims  ≥65  years  or  younger  adults  who  have  chronic  disease  or
tem
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data  are  available  regarding  pneumococcal  disease
in relation  to  the  Hajj,  and  more  studies  are  needed
before  an  ofﬁcial  recommendation  can  be  made.
The Gulf  Advocacy  Group  believes  there  is  a clear
need for  unity  in  recommendations  regarding  pneu-
mococcal  vaccination  and  proposes  that  standard
clinical  practice  be  based  on  data  and  clear  and
well-supported  guidelines.
A number  of  barriers  hinder  the  successful
implementation  of  vaccination  recommendations
in adults  [58].  Barriers  include  general  low  health
awareness and  poor  knowledge  of  the  safety  and
beneﬁts  of  vaccination  in  adults.  A  major  bar-
rier for  potential  vaccine  recipients  is  missed
opportunities to  have  vaccination  recommended
and administered  during  encounters  with  health-
care professionals  in  primary-  and  community-care
[59,60],  perhaps  because  of  an  incomplete  under-
standing  of  the  seriousness  of  pneumococcal
disease  in  older  adults  [61].  Additional  barriers
speciﬁc to  the  Gulf  States  are  inconsistencies  in
reimbursement  and  in  healthcare  systems/policies
between the  countries.
Physicians,  both  in  primary-  and  community-
care, play  a  key  part  in  adult  pneumococcal
disease  prevention,  diagnosis  and  referral.  In  con-
trast, other  stakeholders,  such  as  policy  makers,
•ayers,  media  and  the  public,  have  an  incomplete
wareness of  and  commitment  to  vaccination  in
dults. Raising  awareness  among  physicians  is  crit-
cal to  increasing  vaccine  uptake  but  will  require
he implementation  of  clear  recommendations  and
ools to  motivate  physicians  to  vaccinate  adults.
onclusions: call to action
he  Gulf  Advocacy  Group  calls  on  healthcare
roviders and  policy  makers  in  the  Gulf  States  to
ake steps  toward  addressing  unmet  needs  to  ease
he burden  of  pneumococcal  disease  in  adults.
ptimized surveillance systems and
pidemiology studies
 Require  that  current  national  epidemiology  data
on adult  pneumococcal  disease  (e.g.,  IPD  and
CAP) from  the  region  be  available  through
standardized  protocols  that  are  optimized  to  gen-
erate consistent  and  comparable  data.
 Conduct  sentinel  studies  at selected  locations
to establish  the  actual  incidence,  morbidity  and
mortality  of  IPD  and  CAP  across  the  Gulf  States.
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accination recommendations
 IPD  and  CAP  represent  signiﬁcant  risks  for  adults,
and this  burden  may  be  reduced  with  the  imple-
mentation of  effective  vaccination  programs.
 The  implementation  of  recommendations  should
be gradual  and  based  on  available  resources
within each  country.
 Vaccine  recommendations  should  consider  spe-
ciﬁc high-risk  medical  groups.
 There  should  also  be  provision  for  speciﬁc  groups,
such  as  pilgrims,  travelers  or  nomadic  individ-
uals, and  in  speciﬁc  situations,  such  as  prisoners
and police  recruits.
oordinated awareness and implementation
fforts
 Data  on  the  pneumococcal  disease  burden  and
information  about  successful  vaccination  pro-
grams  should  be  communicated  beyond  the
specialist community  to  healthcare  profession-
als, to  the  public  and  to  policy  makers  to  raise
awareness of  adult  pneumococcal  disease.
 Public  health  policy  and  reimbursement  deci-
sions should  be  made  to  ensure  that  sufﬁcient
resources are  allocated  to  the  prevention  of
pneumococcal disease  in  adults.
 Education  programs  with  clear  messages  should
be delivered  to  multiple  audiences,  including
primary- and  community-care  physicians.
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